# Eli Lilly and Company: Phase 2 study completed, 367 enrolled (Obesity, Overweight)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Eli Lilly and Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
| NCT ID | NCT06603571 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Obesity; Overweight |
| Intervention types | drug |
| Target enrollment | 367 |
| Site countries | United States, Argentina |
| Posted | 2024-09-19 |
| Planned start | 2024-09-20 |
| Event | Completed |
| Event date | 2026-09-14 |
| Last update posted | 2026-09-29 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 367 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06603571). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.